Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Stock Watch: Digging Holes And Clutching At Straws In Biotech R&D

Tenacity Is Not Always A Virtue

Sep 27 2022

• By Andy Smith

Andy Smith — ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Related Content

Clovis Withdraws Rubraca’s Original Ovarian Cancer Indication Shows FDA Emphasis On Survival Data

Jun 21 2022

Stock Watch: The Two Sides Of A Complete Response Letter

Apr 12 2021

Future Of Acadia’s Nuplazid In Alzheimer’s Psychosis Unclear After CRL

Aug 05 2022

EMA Restricts Rubraca’s Use Due To Concerns Over Benefit & Safety

Jul 27 2022

Spectrum’s Delay In Starting Confirmatory Trial Of Poziotinib Troubles US FDA

Sep 20 2022

Related Companies

Acadia Pharmaceuticals Inc.

Clovis Oncology, Inc.

Spectrum Pharmaceuticals, Inc.

Amgen, Inc.

Additional Topics

Complete Response Letters Clinical Trials Drug Review Research & Development Strategy Stock Watch BioPharmaceutical

More from Stock Watch

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window